Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of an investigational quadrivalent meningococcal conjugate vaccine called MenACYW compared to locally licensed meningococcal vaccines in healthy infants and toddlers in China. The study focuses on children aged 2 to 23 months and aims to understand how well the vaccine triggers protection against meningococcal infection. This is a Phase 3, randomized, quadruple-blind study conducted to prevent meningococcal infection in this young population. Participants are divided into cohorts based on age groups and receive different vaccine schedules. Cohort I includes children aged 12 to 23 months receiving two doses of MenACYW or the comparator vaccine. Cohort II includes children aged 6 to 11 months receiving two primary doses plus a booster dose for one group. Cohort III includes children aged 2 to 5 months who receive three primary doses plus a booster dose at 12 or 18 months. Blood samples are collected before and after vaccinations to assess immune response, and telephone follow-ups and safety visits are conducted to monitor adverse events and vaccine safety. During the study, participants attend multiple vaccination visits and blood draws at specified days and months after birth, depending on their cohort. Telephone calls are scheduled shortly after each vaccination and monthly for five months following the last visit to check participant health and safety. Researchers measure antibody levels against meningococcal serogroups and track any immediate or delayed adverse reactions. The study duration varies by cohort, lasting from about 7 months to up to 21 months including safety follow-up after the last dose.